Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition

Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.

Sanofi has agreed a €45 per share cash deal to acquire Ablynx NV, representing a total deal value of about €3.9bn. The Belgian firm has accepted the offer, after rejecting bids from the Danish diabetes and hemophilia therapy maker Novo Nordisk AS over the past few weeks. Novo's most recent disclosed all-cash bid was worth €2.6bn, 50% lower than Sanofi's. (Also see "Novo Nordisk Offers €2.6bn For Ablynx" - Scrip, 8 January, 2018.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By 

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By 

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.